• E-mail :[email]
  • Phone : +33 5 62 74 83 78
  • Location : Toulouse, France
Last update 2012-03-12 10:50:30.945

Jean-Charles Guéry PhD Immunology

Course and current status

2011-present: Group leader "Estrogens & calcium channels in autoimmunity and allergy", INSERM U1043, CPTP, Toulouse (Dir Roland Liblau)

2002-2011: Group leader at INSERM U563 (Dir. G. Delsol), CPTP, Toulouse

1995-2002: Group leader (CR/DR2 INSERM), INSERM U28 (Dir. Ph. Druet), Toulouse

1993-1995: Senior post-doc (Dr L. Adorini), Roche Milano Ricerche, Milano, Italie

1990-1992: Post-doc fellow (Dr L. Adorini), Sandoz Pharma Ltd, CH-4002 Basel, Switzerland

1989-1990: Head Immunotoxicology Unit, Institut de Recherche sur la Sécutité du Médicament, Rhône-Poulenc Santé, Paris.

 

Scientific summary

From 1991-1995, as a post-doctoral fellow in Dr Luciano Adorini’s lab, I have been studying several aspects of self and non-self antigen presentation by dendritic cells and their impact on tolerance induction and immunity. In this field, I contributed to define the in vivo mechanisms of MHC class II-specific peptide blockers as selective inhibitors of CD4 T cell responses.  I also demonstrated that chronic sustained soluble antigen administration is a selective trigger of Th2 responses in vivo

Since 1996, I established my research group in Toulouse focused on the study of the regulation of T helper cell activation and differentiation, particularly Th2 cells, in experimental models of allotransplantation and allergic diseases. In the context of allotransplantation, we showed that cytotoxic lymphocytes (CTL, NK cells) have important regulatory functions through their capacity to eliminate, whithin draining lymph nodes, donor-derived dendritic cells bearing allo-MHC products. Regarding Th2-cell mediated immune disorders, we identified a sub-class of Ca-channels, specifically expressed by Th2-cells and implicated in their Th2 effector functions. We then demonstrated that they represent potential therapeutic targets for the treatment of allergic diseases.

The current projects of my research group mainly focus on the study estrogen receptor (ER) signaling on the regulation of adaptive and innate immune responses, and its potential implication in the pathogenesis of autoimmune diseases.

 

Image d’exemple